论文部分内容阅读
目的观察肾康注射液联合奥美沙坦酯治疗高血压合并痛风性肾病的临床疗效与安全性。方法将2014年1月~2015年10月我院收治的190例高血压合并痛风性肾病患者随机分为2组。对照组(n=95)给予奥美沙坦酯片治疗,每日1次,每次20 mg口服;观察组(n=95)在对照组基础上加用肾康注射液治疗,每日1次,每次100 mL静脉滴注。两组治疗疗程均为4周。观察并记录两组患者治疗前后血压、肾功能及不良反应发生情况。结果观察组总有效率为87.36%,对照组总有效率为69.70%,两组比较差异有统计学意义(χ~2=5.08,P<0.05)。治疗后两组血压、尿素氮、肌酐、24 h尿蛋白及微量尿蛋白均有明显下降,其中观察组下降更显著,与对照组比较差异有统计学意义(P<0.05)。两组间不良反应发生率比较,差异无统计学意义(P>0.05)。结论肾康注射液联合奥美沙坦酯能有效降低高血压合并痛风性肾病患者的血压,并改善其肾脏功能,延缓病情发展,且安全可靠。
Objective To observe the clinical efficacy and safety of Shenkang injection combined with olmesartan medoxomil in patients with hypertension and gouty nephropathy. Methods From January 2014 to October 2015 in our hospital, 190 cases of hypertensive patients with gouty nephropathy were randomly divided into two groups. The control group (n = 95) was treated with olmesartan ester tablets once daily for 20 mg orally. The observation group (n = 95) was treated with Shenkang injection once a day , Each 100 mL intravenous infusion. The two groups were treated for 4 weeks. Observe and record the two groups of patients before and after treatment of blood pressure, renal function and adverse reactions. Results The total effective rate was 87.36% in the observation group and 69.70% in the control group. The difference between the two groups was statistically significant (χ ~ 2 = 5.08, P <0.05). After treatment, blood pressure, blood urea nitrogen, creatinine, 24 h urinary protein and microalbuminuria decreased significantly in both groups. The decrease in the observation group was more significant than that in the control group (P <0.05). Adverse reactions between the two groups, the difference was not statistically significant (P> 0.05). Conclusion Shenkang injection combined with olmesartan medoxomil can effectively reduce the blood pressure in hypertensive patients with gouty nephropathy and improve its renal function, delay the progression of the disease and be safe and reliable.